4791-23-5 Usage
Description
N-(Anilinocarbonyl)-2-chloroacetamide is an organic chemical compound with the molecular formula C9H8ClNO2. It features an anilinocarbonyl group and a 2-chloroacetamide group, making it a versatile building block in organic synthesis and pharmaceutical research. N-(ANILINOCARBONYL)-2-CHLOROACETAMIDE is known for its ability to engage in a range of chemical reactions, which contributes to its potential applications in drug development and as a precursor for synthesizing other organic compounds. Due to its potential hazardous properties, it is crucial to handle and utilize this compound with care in a controlled laboratory setting.
Uses
Used in Pharmaceutical Research:
N-(Anilinocarbonyl)-2-chloroacetamide is utilized as a building block in pharmaceutical research for its capacity to participate in various chemical reactions. This makes it a valuable component in the development of new drugs, as it can be modified and combined with other compounds to create novel therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, N-(Anilinocarbonyl)-2-chloroacetamide serves as a key precursor for the synthesis of other organic compounds. Its unique structure allows it to be a starting point for creating a variety of complex organic molecules, which can be used in different industries, including pharmaceuticals, agrochemicals, and materials science.
Used in Drug Development:
N-(Anilinocarbonyl)-2-chloroacetamide has potential applications in the development of new drugs. Its ability to engage in multiple chemical reactions makes it a promising candidate for creating innovative pharmaceuticals that can address unmet medical needs or improve upon existing treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 4791-23-5 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,7,9 and 1 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 4791-23:
(6*4)+(5*7)+(4*9)+(3*1)+(2*2)+(1*3)=105
105 % 10 = 5
So 4791-23-5 is a valid CAS Registry Number.
InChI:InChI=1/C9H9ClN2O2/c10-6-8(13)12-9(14)11-7-4-2-1-3-5-7/h1-5H,6H2,(H2,11,12,13,14)
4791-23-5Relevant articles and documents
Discovery of 5-Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety as Orally Bioavailable Reversal Agents against P-Glycoprotein-Mediated Mutidrug Resistance
Wang, Bo,Ma, Li-Ying,Wang, Jing-Quan,Lei, Zi-Ning,Gupta, Pranav,Zhao, Yuan-Di,Li, Zhong-Hua,Liu, Ying,Zhang, Xin-Hui,Li, Ya-Nan,Zhao, Bing,Chen, Zhe-Sheng,Liu, Hong-Min
, p. 5988 - 6001 (2018)
P-glycoprotein (ABCB1)-mediated multidrug resistance (MDR) has become a major obstacle in successful cancer chemotherapy, which attracted much effort to develop clinically useful compounds to reverse MDR. Here, we designed and synthesized a novel series o
Design, Synthesis, and Antitumor Activity Evaluation of Trifluoromethyl-Substituted Pyrimidine Derivatives Containing Urea Moiety
Chao, Gao,Heyi, Yan,Honglin, Dai,Hongmin, Liu,Jiaxin, Zheng,Lihong, Shan,Limin, Liu,Luye, Zhang,Na, Li,Qiurong, Zhang,Tao, Wang,Xiujuan, Liu,Yang, Zhang,Zhengjie, Wang
, p. 1301 - 1311 (2021/12/23)
Abstract: In order to find efficient new antitumor drugs, a series of novel pyrimidine derivatives containing urea moiety were designed and synthesized, and the antitumor activity of four human tumor cells was evaluated by MTT analysis. The results showed that most of the target compounds exhibited moderate antitumor activity. In particular, the IC50 (concentration required to achieve 50% inhibition of the tumor cell proliferation) value of compound 2-((4-(4-ethylphenoxy)-6-(trifluoromethyl)pyrimidin-2-yl)thio)-N-((4-ethylphenyl)carba-moyl)acetamide for MGC-803 (human gastric carcinoma cell line) was 2.51 ± 0.17 μmol L–1, the anti-proliferative activity was significantly better than the positive control drug 5-fluorouracil. Molecular docking revealed that this compound can bind well to the active site of epidermal growth factor receptor (EGFR), and it may become a potential antitumor drug.
ANTIBACTERIAL THERAPEUTICS AND PROPHYLACTICS
-
Paragraph 00390; 00393, (2017/02/24)
The present disclosure relates generally to novel molecules, compositions, and formulations for treatment of bacterial infections in general and more specifically to bacterial infections with antibiotic resistant pathogens.
